The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions in Alopecia Areata
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Celiac Disease
- Allergic Rhinitis
- Alopecia Areata
- Ankylosing Spondylitis
- Vitiligo
- Type 1 Diabetes
- Ulcerative Colitis
- Anxiety Disorders
- Asthma
- Rheumatoid Arthritis
- Atopic Dermatitis
- Crohn Disease
- Depressive Episode
- Grave's Disease
- Psoriatic Arthritis
- Systemic Lupus Erythematosus
- Psoriasis
- Hashimoto Thyroiditis
- Recurrent Depressive Disorder
- Multiple Sclerosis
- Pernicious Anemia
- Polymyalgia Rheumatica
- Sjogren's Syndrome
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Retrospective
Participation Requirements
- Age
- Younger than 125 years
- Gender
- Both males and females
Description
The overall purpose of the first study (Study 1) is to describe the epidemiology of Alopecia areata (AA) and to assess the current level of primary care service utilisation and management patterns associated with patients diagnosed with AA. The overall purpose of the second study (study 2) is to ass...
The overall purpose of the first study (Study 1) is to describe the epidemiology of Alopecia areata (AA) and to assess the current level of primary care service utilisation and management patterns associated with patients diagnosed with AA. The overall purpose of the second study (study 2) is to assess the prevalence and incidence of mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in adult patients diagnosed with AA relative to a control population of patients without a diagnosis of AA. In addition, the study will determine both the treatment, 'sick day' and unemployment burden. Treatment burden comprises that of medications and psychological interventions used to treat mental health conditions in adult patients diagnosed with Alopecia areata. The overall purpose of the third study (Study 3) is to assess the prevalence and incidence of atopic and autoimmune conditions in adult patients diagnosed with AA relative to a control population of patients without AA.
Tracking Information
- NCT #
- NCT04239521
- Collaborators
- Pfizer
- University of Surrey
- Investigators
- Study Director: Andrew McGovern, MD Momentum Data
Get Well Soon